Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Celyad OncologyCLYYF +40.00%28 3-Year EPS without NRI Growth Rate is 69.50% as of Dec. 2025, which is 529% above its 10-year median of 11.05. GuruFocus rates CLYYF with a GF Scoreâ„¢ of 28/100 and a GF Valueâ„¢ of $0.15 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,160 Biotechnology companies, Celyad Oncology ranks better than 92.5% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 69.50% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 56.10% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 32.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Celyad Oncology was 69.50% per year. The lowest was -24.90% per year. And the median was 11.05% per year.
Celyad Oncology (OTCPK:CLYYF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Celyad Oncology 3-Year EPS without NRI Growth Rate Related Terms
CLYYF vs VRTX, REGN, MRNA: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Celyad Oncology's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celyad Oncology 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celyad Oncology's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Celyad Oncology's 3-Year EPS without NRI Growth Rate falls into.
Celyad Oncology 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 69.50% mean?
Celyad Oncology (CLYYF) has a 3-Year EPS without NRI Growth Rate of 69.50% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Celyad Oncology and its competitors. This is 529% above median its historical median of 11.05. According to the industry distribution chart, Celyad Oncology ranks #87 out of 1160 companies in the Biotechnology industry, placing it in the top 7.5%.
Is Celyad Oncology's 3-Year EPS without NRI Growth Rate too high?
Celyad Oncology's current 3-Year EPS without NRI Growth Rate of 69.50% is 529% above median its 10-year median of 11.05. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Celyad Oncology's value of 69.50% is 329% above this industry median. Based on the distribution chart, Celyad Oncology ranks #87 out of 1160 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Celyad Oncology has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Celyad Oncology ranks #87 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places Celyad Oncology in the top 8% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Celyad Oncology's value of 69.50% is 329% above this benchmark. While the company's 10-year median is 11.05 vs. the industry median of 16.20, Celyad Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celyad Oncology's current 3-Year EPS without NRI Growth Rate of 69.50% is 329% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Celyad Oncology and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celyad Oncology's current 3-Year EPS without NRI Growth Rate is 69.50%, which is 529% above median its own 10-year median of 11.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Based on GuruFocus' analysis, Celyad Oncology (CLYYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.28 — trading 86.7% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 69.50%, which is 529% above median its 10-year median of 11.05 and 329% above the Biotechnology industry median of 16.20. Celyad Oncology's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current 3-Year EPS without NRI Growth Rate is 69.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celyad Oncology (CLYYF) Overvalued in 2026?
Based on GuruFocus' analysis, Celyad Oncology stock appears to be overvalued.
The current stock price of $0.28 is trading 86.7% above its estimated GF Value™ of $0.15.
GuruFocus considers Celyad Oncology to be Significantly Overvalued.
Key valuation signals for CLYYF:
3-Year EPS without NRI Growth Rate: 69.50% (529% above median its 10-year median of 11.05)
GF Value™: $0.15 vs. price of $0.28 (86.7% above fair value)
Industry Position: 329% above the Biotechnology median (#87 of 1160)
No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
28GF Score
Get the complete analysis for CLYYF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYYF has been successfully added to your 
